Cure My Disease

Don't miss your cure!

 Log in / Sign up

Major study aims to better measure muscular dystrophy progression

NCT ID NCT05989620

Recruiting now Knowledge-focused Sponsor: Virginia Commonwealth University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This 24-month observational study will follow up to 1000 people with certain types of muscular dystrophy (LGMD, DM2, and late-onset Pompe disease) aged 6-50. Researchers want to see if specific physical tests, like the North Star Assessment and a 100-meter walk, are good ways to track the disease over time. The goal is to improve how we measure the condition in future studies, not to test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LATE-ONSET POMPE DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autosomal dominant limb-girdle muscular dystrophy type 1D (DNAJB6) autosomal dominant limb-girdle muscular dystrophy type 1F autosomal dominant limb-girdle muscular dystrophy type 1G autosomal dominant limb-girdle muscular dystrophy type 1H autosomal recessive limb-girdle muscular dystrophy type 2A autosomal recessive limb-girdle muscular dystrophy type 2B autosomal recessive limb-girdle muscular dystrophy type 2C autosomal recessive limb-girdle muscular dystrophy type 2D autosomal recessive limb-girdle muscular dystrophy type 2E autosomal recessive limb-girdle muscular dystrophy type 2F autosomal recessive limb-girdle muscular dystrophy type 2G autosomal recessive limb-girdle muscular dystrophy type 2I autosomal recessive limb-girdle muscular dystrophy type 2J autosomal recessive limb-girdle muscular dystrophy type 2K autosomal recessive limb-girdle muscular dystrophy type 2L autosomal recessive limb-girdle muscular dystrophy type 2M autosomal recessive limb-girdle muscular dystrophy type 2N autosomal recessive limb-girdle muscular dystrophy type 2O autosomal recessive limb-girdle muscular dystrophy type 2P autosomal recessive limb-girdle muscular dystrophy type 2Q autosomal recessive limb-girdle muscular dystrophy type 2T autosomal recessive limb-girdle muscular dystrophy type 2U autosomal recessive limb-girdle muscular dystrophy type 2W autosomal recessive limb-girdle muscular dystrophy type 2X autosomal recessive limb-girdle muscular dystrophy type 2Y autosomal recessive limb-girdle muscular dystrophy type R18 Emery-Dreifuss muscular dystrophy 2, autosomal dominant glycogen storage disease due to acid maltase deficiency, late-onset limb-girdle muscular dystrophy Limb-girdle muscular dystrophy, type 2E muscular dystrophy Muscular Dystrophy, Limb-Girdle, Type 1C Muscular Dystrophy, Limb-Girdle, Type 1E muscular dystrophy-dystroglycanopathy, type A myotonic dystrophy myotonic dystrophy type 2 rippling muscle disease 2 sarcoglycanopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LGMD1B LGMD1C LGMD1D LGMD1E LGMD1F LGMD1G LGMD1H LGMD2A LGMD2B LGMD2C LGMD2D LGMD2E LGMD2F LGMD2G LGMD2I LGMD2J LGMD2K LGMD2L LGMD2M LGMD2N LGMD2O LGMD2P LGMD2Q LGMD2S LGMD2T LGMD2U LGMD2W LGMD2X LGMD2Y

Contacts and locations

Locations

  • Virginia Commonwealth University

    RECRUITING

    Richmond, Virginia, 23298, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.